Pidilite Inds, Ramsarup Inds & Torrent Pharma Q4 results

CORPORATE SCORECARD

Pidilite Inds net down 21%

Pidilite Industries has reported a net profit of Rs 13.97 crore for the quarter ended March 31, 3006, which is 21.47 per cent lower compared to Rs 17.79 crore for the corresponding quarter last year. Net sales for the period were Rs 206.53 crore compared to Rs 170.75 crore last year, higher by 20.95 per cent.

For the financial year ended March 2006, the company reported a net profit of Rs 90.68 crore as compared to Rs 76.57 crore last year. Net sales for the year were Rs 907.52 crore as compared to Rs 769.48 crore. The board has recommended a dividend of Rs 1.25 per equity share of Re 1 each.

Ramsarup Inds net up 103%

Ramsarup Industries has registered a 103.22-per cent growth in net profit, at Rs 27.80 crore for the financial year 2005-06. Net sales in 2005-06 stood at Rs 1,018.03 crore, 16.01 per cent higher than the corresponding figure last year, which stood at Rs 877.55 crore.

Torrent Pharma net up 4%

Ahmedabad-based pharma major, Torrent Pharmaceuticals, registered consolidated net profit of Rs 51 crore in 2005-06, against Rs 49 crore during the previous year.

The growth in net profit was lower due to higher depreciation charge on account of commissioning of new manufacturing facilities, higher deferred tax expense and a one-time exceptional write-off.

The consolidated operating profits (PBDIT) of company were also at a historic high of Rs 108 crore in 2005-06, showing a growth of 46 per cent from Rs 74 crore in the previous year.

In the company's audited financial results for the year 2005-06, the consolidated sales stood at a record Rs 1001-crore, up 77 per cent from Rs 565 crore during the previous year.

Consolidated international sales grew 215 per cent, from Rs 137 crore in the previous fiscal to Rs 431 crore during the year.

The domestic formulation business registered sales of Rs 444 crore as against sales of Rs 333 crore during the previous year, registering a 33-per cent growth.

However, in the fourth quarter ended March 2006, the consolidated sales of the company grew 104 per cent, to Rs 248 crore from Rs 122 crore in the corresponding period of the previous year.

This was driven by a strong growth of 175 per cent in international sales and 71 per cent in the domestic formulation business, with adjustments for VAT related impact in the comparative quarter leading to a 14-per cent growth.

During the year, Torrent Pharma's board approved the proposal to split the face value of its equity shares from Rs 10 to Rs 5 and to issue bonus equity shares in the ratio of one bonus share for every share on a post-split basis.

The board has recommended an increased dividend of Rs 2.5 per share for the year, subject to approval at the ensuing AGM. During the year, Torrent Pharma filed four ANDAs and three DMFs with USFDA as part of its US operations.

Visa Steel net up 90%

Visa Steel has recorded a 90-per cent rise in profit after tax (PAT) at Rs 12.50 crore for the year ended March 31, 2006.

Revenue of the company grew by 52.60 per cent, to Rs 385 crore, whereas Ebidta grew by 182 per cent, to Rs 36.70 crore in 2005-06.